<DOC>
	<DOCNO>NCT01051960</DOCNO>
	<brief_summary>The purpose study determine clinical characteristic hemodynamic profile predict exercise induce pulmonary hypertension 15 patient systemic sclerosis . The study also aim determine effectiveness Ambrisentan subject exercise induced Pulmonary Arterial Hypertension ( PAH ) scleroderma</brief_summary>
	<brief_title>Exercise Induced Pulmonary Hypertension Systemic Sclerosis Treatment With Ambrisentan</brief_title>
	<detailed_description>The current literature address therapy patient rest PAH , diagnose right heart catheterization . However , World Health Organization ( WHO ) also recognize defines exercise induce pulmonary arterial hypertension ( ex-PAH ) , may precede development rest PAH . The natural progression PAH , especially exercise , well delineate . An exercise hemodynamic study previously show normal healthy subject mean pulmonary pressure exceed 30mmHg even maximal cardiac output . A prior study evaluate exercise Doppler echocardiography systemic sclerosis patient normal rest echocardiogram , find abnormal response define estimate right ventricular systolic pressure great 40 mmHg . In study , 6.6 % patient progress rest PAH followup period 12 month . Limited data available regard prevalence ex-PAH systemic sclerosis use right heart catheterization .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<criteria>1 . Systemic Sclerosis diagnose American College Rheumatology consensus statement include follow : Limited Diffuse Sine Scleroderma 2 . Patients must willing able undergo right heart catheterization low extremity cycle ergometry 3 . Mean pulmonary artery pressure ( mPAP ) &gt; 30mmHg exercise ; PCWP ≤ 15mmHg RHC rest 4 . Men woman , age 18 year age old 5 . Standard adjunctive medication allow concurrently study discretion treat pulmonologist rheumatologist , include digoxin , diuretic , anticoagulant ( e.g . warfarin ) , stable immunosuppression antifibrotic therapy least one month prior enrollment 1 . Resting PAH ( mPAP &gt; 25mmHg ) right heart catheterization 2 . Other known cause PAH include prior venous thromboembolism , HIV infection , chronic liver disease portal hypertension , leave ventricular systolic dysfunction ( e.g . LVEF &lt; 40 % ) , congenital cause PAH 3 . Severe hepatic disease preclude use ambrisentan ( AST/ALT ≥3x ULN ) . 4 . Women pregnant breastfeeding . 5 . Concurrent therapy prostanoid prostanoid analogue , PDE5 inhibitor , enrol another active clinical study . 6 . Use prostacyclin endothelial receptor antagonist ( ERA ) within 30 day study entry . 7 . Bed wheel chair bound baseline 6Minute Walk distance ( 6MWD ) less 150 meter . 8 . Childbearing capable woman unwilling unable use acceptable method avoid pregnancy entire study period . 9 . New York Heart Association ( NYHA ) Classification : Class IV 10 . Renal dysfunction ( serum creatinine &gt; 2.5mg/dL ) . 11 . Uncontrolled sleep apnea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Systemic Sclerosis</keyword>
	<keyword>connective tissue disease</keyword>
	<keyword>Shortness breath</keyword>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>